en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Faq › Measurement And Storage Practices — Reference Sheet

Measurement And Storage Practices — Reference Sheet

By Editorial Desk · published 2026-05-08 · last reviewed 2026-06-18 · Faq

AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-06-18. Anything still debated is marked as such rather than presented as settled.

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form
SolubilitySoluble in waterAlso soluble in aqueous buffers
Storage temperature-20°C or belowProtect from light and moisture
Analytical methodRP-HPLCPurity and identity assessment
Mass confirmationMass spectrometryVerifies molecular mass

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Related pages on this site

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Supporting material

Sunak announces a further £2.5bn in military aid for Ukraine during 2024. British Post Office scandal: The BBC reports that Post Office managers threatened and lied to the broadcaster in an attempt to conceal key evidence ahead of the broadcast of the 2015 Panorama documentary that brought the Horizon IT scandal to public attention. Financial experts estimate the Post Office may have underpaid £100m in tax because of how it declared compensation payments to victims of the Horizon IT scandal. 13 January Thousands of people join a pro-Palestinian march in London calling for a ceasefire in Gaza due to the ongoing Gaza war. A fleet of electric buses are withdrawn in South London after a fire starts on the 200 hybrid electric bus on 11 January. A new biography of King Charles III by Daily Mail royal correspondent Robert Hardman says that a memo written by Queen Elizabeth II's private secretary, Sir Edward Young, reports that the Queen's final moments in September 2022 were "very peaceful". Five cross-Channel migrants, the first seen in 2024, arrive in a Border Force boat in Kent after being picked up while crossing from France. 14 January Five people die when a small boat overturns in French waters as around 70 people try to board it in an attempt to migrate across the English Channel to the UK. Thousands of people attend a pro-Israel rally in London to mark 100 days since the 7 October attack and call for the release of all hostages from Gaza. Six people are arrested over a plot by the protest group Palestine Action to disrupt the London Stock Exchange.

=== Branched-chain amino acids === Several studies have attempted to decrease the synthesis of serotonin by administering branched-chain amino acids and inhibiting the transport of tryptophan across the blood brain barrier. The studies performed resulted in little or no change in performance between increased BCAA intake and placebo groups. One study in particular administered a carbohydrate solution and a carbohydrate + BCAA solution. Both of the groups were able to run for longer before fatigue compared to the water placebo group. However, both the carbohydrate and the carbohydrate + BCAA groups had no differences in their performance. Branch-chained amino acid supplementation has proven to have little to no effect on performance. There has been little success utilizing neurotransmitter precursors to control central nervous system fatigue. One review hypothesized that the inconsistency with BCAA administration was the result of ammonia accumulation as a result of increased BCAA oxidation.

== Bibliography == Harrison, Alex. G. (1992). Chemical ionization mass spectrometry (2. ed.). Boca Raton, Fla. [u.a.]: CRC Press. ISBN 9780849342547. Hunt, Donald F.; McEwen, Charles N.; Harvey, T. Michael. (2002). "Positive and negative chemical ionization mass spectrometry using a Townsend discharge ion source". Analytical Chemistry. 47 (11): 1730–1734. doi:10.1021/ac60361a011. Dass, Chhabil (2007). Fundamentals of contemporary mass spectrometry ([Online-Ausg.]. ed.). Hoboken, N.J.: Wiley-Interscience. ISBN 9780470118498.

Sources: en.wikipedia.org

Notes from published material

Significant controversy surrounds female genital mutilation (FGM), with the World Health Organization (WHO) being one of many health organizations that have campaigned against the procedures on behalf of human rights, stating that "FGM has no health benefits" and that it is "a violation of the human rights of girls and women" which "reflects deep-rooted inequality between the sexes". The practice has existed at one point or another in almost all human civilizations, most commonly to exert control over the sexual behavior, including masturbation, of girls and women, but also to change the clitoris' appearance. Custom and tradition are the most frequently cited reasons for FGM, with some cultures believing that not performing it has the possibility of disrupting the cohesiveness of their social and political systems, such as FGM also being a part of a girl's initiation into adulthood. Often, a girl is not considered an adult in an FGM-practicing society unless she has undergone FGM, and the "removal of the clitoris and labia – viewed by some as the male parts of a woman's body – is thought to enhance the girl's femininity, often synonymous with docility and obedience". Female genital mutilation is carried out in several societies, especially in Africa, with 85 percent of genital mutilations performed in Africa consisting of clitoridectomy or excision, and to a lesser extent in other parts of the Middle East and Southeast Asia, on girls from a few days old to mid-adolescent, often to reduce the sexual desire to preserve vaginal virginity.

== Life and work == Lundsgaard was born in Copenhagen where his father was a physician who came from the Gundelach family of lawyers and civil servants His father received a gold medal for his work on prostatic hypertrophy from the University of Copenhagen. At school he played guitar as a hobby. In 1917 he completed school and entered medical studies. He completed studies in 1923 and worked at the institute of medical physiology under Valdemar Henriques. He received a doctorate in 1929. His major finding was on muscle contraction when glycolysis was blocked by mono-iodoacetate. He found that energy was drawn from the phosphate bond energy and he published the findings in 1930. Until then it was believed that glycolysis was the main source of energy. Creatine phosphate was independently identified in muscle by the Eggletons and by Cyrus H. Fiske and Subbarow in 1926. From 1934 he began to work on phlorizin and its metabolic effects. This was continued with insulin in studies of perfused livers. In 1938 he examined the metabolism of alcohol and its conversion to acetic acid by the liver. He received the Thunberg medal in 1960 and the Anders Jahre prize for 1964. Herman Kalckar was among his students. He retired in 1967 and died from renal cancer the next year.

This allowed for two Soviet Republics, Ukraine and Byelorussia, (as well as the USSR as a whole) to join the United Nations General Assembly as founding members in 1945. The Soviet currency Soviet ruble banknotes all included writings in national languages of all the 15 union republics. All of the former Republics of the Union are now independent countries, with ten of them (all except the Baltic states, Georgia and Ukraine) being very loosely organized under the heading of the Commonwealth of Independent States. The Baltic states assert that their incorporation into the Soviet Union in 1940 (as the Lithuanian, Latvian, and Estonian SSRs) under the provisions of the 1939 Molotov–Ribbentrop Pact was illegal, and that they therefore remained independent countries under Soviet occupation. Their position is supported by the European Union, the European Court of Human Rights, the United Nations Human Rights Council and the United States. In contrast, the Russian government and state officials maintain that the Soviet annexation of the Baltic states was legitimate.

Sources: en.wikipedia.org

Frequently asked questions

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

What are the recommended storage conditions for AOD-9604?

Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.

What quality issues can arise with AOD-9604 products?

Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network